Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GRAILGRAL -0.54%11 Days Payable is 9.49 as of Jun. 2026, which is 57% below its 10-year median of 22.17. GuruFocus rates GRAL with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, GRAIL ranks worse than 96.32% on this metric.
GRAIL's average Accounts Payable for the
three
months ended in Jun. 2026 was $6.0 Mil. GRAIL's Cost of Goods Sold for the
three
months ended in Jun. 2026 was $57.3 Mil.
Hence, GRAIL's Days Payable for the
three
months ended in Jun. 2026 was 9.49.
The historical rank and industry rank for GRAIL's Days Payable or its related term are showing as below:
GRAL'
s Days Payable Range Over the Past 10 Years
Min: 6.03 Med: 22.17 Max: 33.71
Current: 7.97
During the past 6 years, GRAIL's highest Days Payable was 33.71. The lowest was 6.03. And the median was 22.17.
GRAL's Days Payable is ranked worse than 96.32% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs GRAL: 7.97
GRAIL's Days Payable
declined
from Jun. 2025 (10.31) to Jun. 2026 (9.49).
It may suggest that GRAILaccelerated paying its suppliers.
The historical data trend for GRAIL's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, GRAIL's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRAIL Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's Days Payable distribution charts can be found below:
* The bar in red indicates where GRAIL's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
GRAIL's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRAIL (GRAL) has a Days Payable of 9.49 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GRAIL and its competitors. This is 57% below median its historical median of 22.17. Over the past decade, GRAIL's Days Payable has ranged from 6.03 to 33.71. According to the industry distribution chart, GRAIL ranks #183 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 96.3%.
Is GRAIL's Days Payable too high?
GRAIL's current Days Payable of 9.49 is 57% below median its 10-year median of 22.17. Over the past 10 years, this metric has ranged from a low of 6.03 to a high of 33.71. The Medical Diagnostics & Research industry median Days Payable is 64.64. GRAIL's value of 9.49 is 85.3% below this industry median. Based on the distribution chart, GRAIL ranks #183 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GRAIL has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's Days Payable compare to ADPT and CDNA?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #183 out of 190 companies for Days Payable. This places GRAIL in the lower half of its industry. The industry median Days Payable is 64.64. GRAIL's value of 9.49 is 85.3% below this benchmark. Historically, GRAIL's own Days Payable has ranged from 6.03 to 33.71 over the past decade. While the company's 10-year median is 22.17 vs. the industry median of 64.64, GRAIL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRAIL's current Days Payable of 9.49 is 85.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current Days Payable is 9.49, which is 57% below median its own 10-year median of 22.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current Days Payable of 9.49. The current Days Payable is 9.49, which is 57% below median its 10-year median of 22.17 and 85.3% below the Medical Diagnostics & Research industry median of 64.64. GRAIL's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For GRAIL (GRAL), the current Days Payable is 9.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
11GF Score
Get the complete analysis for GRAL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRAL has been successfully added to your 
